<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03763357</url>
  </required_header>
  <id_info>
    <org_study_id>1809400414</org_study_id>
    <nct_id>NCT03763357</nct_id>
  </id_info>
  <brief_title>Acute Effects of Leg Heating on Skeletal Muscle Blood Flow</brief_title>
  <official_title>Acute Effects of Leg Heating on Skeletal Muscle Blood Flow in Patients With Symptomatic Peripheral Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bruno Roseguini, PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Purdue University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to apply local heat to the legs, thighs and buttocks of patients&#xD;
      with peripheral arterial disease and use PET/CT imaging with an injectable stable radiotracer&#xD;
      to study direct measurement of blood flow in the legs pre and post heat treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cilostazol is the only effective medication available to treat walking pain (intermittent&#xD;
      claudication) and it has multiple side effects. Overall improvement in walking performance in&#xD;
      patients who use cilostazol is small. Endovascular and surgical interventions are effective&#xD;
      alternatives for patients who don't respond to medical therapy, however, these procedures are&#xD;
      costly and only applicable to patients with certain lesions types and carry a high risk of&#xD;
      restenosis.&#xD;
&#xD;
      Heat therapy (HT) is an emerging non-invasive approach that has been shown to enhance&#xD;
      vascular function of the leg in old individuals. The objective of this study is to test the&#xD;
      hypothesis that a single session of heat therapy will increase local muscle tissue blood flow&#xD;
      in the calf of patients with PAD as assessed by PET/CT imaging of generator-based 62Cu-ETS.&#xD;
&#xD;
      Subjects who have met inclusion criteria will volunteer for a single experimental visit.&#xD;
      Participants will wear the water circulating pants and asked to rest supine for 30 minutes&#xD;
      inside the scanner. Water at 43 degrees C will be perfused through the pants for 90 minutes&#xD;
      with the goal to increase skin temperature in the calf to 39 degrees C. IV injections of&#xD;
      62Cu-ETS and subsequent perfusion imaging will be performed at the end of the 30 minute&#xD;
      baseline period, after 45 minutes of heat therapy and at the end of the intervention (90&#xD;
      minutes). Due to the short half life of 62Cu, radioactivity from the prior administrations&#xD;
      will not interfere with acquisition of a subsequent PET scan at this timing interval.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All of the subjects in this study will receive leg heat therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in calf blood flow</measure>
    <time_frame>Blood flow measurements will be completed at baseline (0 minutes) and after 45 and 90 minutes of exposure to heat therapy or a control regimen</time_frame>
    <description>Calf muscle perfusion rate (mL⋅min-1⋅g-1) will be obtained after administration of tracer 62Cu-ETS before, during and after exposure to heat therapy or a control intervention. Changes from in perfusion rate from baseline to 45 minutes and 90 minutes of heating or control will be measured.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Heat Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will dress in water-circulating trousers that are connected to a Heat Therapy (HT) pump. Warm water (42-43 degrees C) will be perfused through the pants for 90 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Heat Therapy (HT)</intervention_name>
    <description>Water at 42-43 degrees C will be circulated through the water circulating trousers to obtain calf skin temperature 39 degrees C followed by PET/CT imaging of generator-based 62Cu-ETS.</description>
    <arm_group_label>Heat Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women with a stable symptomatic claudication for &gt;/= 6 months&#xD;
&#xD;
          -  Ankle brachial index &lt; 0.9&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  COPD&#xD;
&#xD;
          -  Critical limb ischemia&#xD;
&#xD;
          -  Prior amputation&#xD;
&#xD;
          -  Exercise-limiting co-morbidity&#xD;
&#xD;
          -  Recent (&lt; 3 months) intra-inguinal revascularization or planned in study period&#xD;
&#xD;
          -  Plans to change medical therapy during duration of study&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  Chronic kidney disease (eGFR &lt; 30)&#xD;
&#xD;
          -  HIV positive, active HBV or HCV disease&#xD;
&#xD;
          -  Presence of an clinical condition that makes the patient not suitable to participate&#xD;
             in the trial&#xD;
&#xD;
          -  Peripheral neuropathy, numbness or paresthesia in the legs&#xD;
&#xD;
          -  Morbid obesity BMI &gt; 36 or unable to fit into water-circulating pants&#xD;
&#xD;
          -  Open wounds or ulcers on the extremity&#xD;
&#xD;
          -  Claustrophobia/unable to tolerate PET/CT scanning&#xD;
&#xD;
          -  Women of child-bearing age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raghu L Motaanahalli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno T Roseguini, PhD</last_name>
    <phone>765-496-2612</phone>
    <email>brosegui@purdue.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janet S Klein, RN, MSN</last_name>
    <phone>317-962-0287</phone>
    <email>jswklein@iupui.edu</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 23, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2018</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Raghu Motaganahalli</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

